Inclusion and Exclusion Criteria
noncardiogenic, atrial tachycardia, ASCVD, unstable angina, infections, valvular stenosis, ventricular outflow tract stenosis, aneurysm rupture, mental disorders, dysfunction or rupture of papillary muscle, heart failure, acute pulmonary embolism, ACS, diabetes
RECURRENCE, SEVERE SINUS BRADYCARDIA, PULMONARY INFARCTION, ATRIAL TACHYCARDIA, UNSTABLE ANGINA, KIDNEY FAILURE, ACUTE CORONARY SYNDROME, ATRIOVENTRICULAR BLOCK, ENDOCARDITIS, INFECTIONS, CARDIAC ARREST, SINUS ARREST, CARDIAC ANEURYSM, VENTRICULAR TACHYCARDIA, ASCVD, DIABETES, HYPERTHYROIDISM, PERICARDITIS, CRITICAL ILLNESS, HEART FAILURE, ANEURYSM RUPTURED, ACUTE PULMONARY EMBOLISM, ATRIAL FLUTTER, COMPLICATIONS, MURAL THROMBUS, MYOCARDIAL INFARCTION, ACUTE MYOCARDITIS, TRANSIENT ISCHEMIC ATTACK, EVENT, DISEASE, HYPERTROPHIC CARDIOMYOPATHY, ATRIAL FIBRILLATION
The participants were recruited from among consecutive patients diagnosed with ASCVD. The inclusion criteria were as follows: (1) age from 18 to 80 years; (2) meeting ASCVD diagnostic criteria, including a history of acute coronary syndrome (ACS), myocardial infarction, stable or unstable angina, transient ischemic attack, surgical history of coronary or peripheral vascular reconstructions, etc; (3) currently taking statins by prescription; (4) no difficulty in using smartphones, essential Chinese reading and writing skills and basic calculation skills; and (5) acceptance of the terms and conditions of the study and signature of the informed consent form.The exclusion criteria were as follows: (1) meeting super high-risk ASCVD diagnostic criteria (diagnostic criteria are determined according to the 2020 Chinese expert consensus on lipid management of very high-risk patients with ASCVD; according to the diagnostic criteria, diagnosed ASCVD patients with one of the following conditions can be diagnosed as super high-risk ASCVD: ASCVD event recurrence; multivessel disease of coronary artery; recent ACS; atherosclerotic vascular disease of heart, brain, or peripheral multivascular bed; LDL-C≥4.9 mmol/L [190 mg/dl]; and diabetes); (2) one or more of the following complications: heart failure, ventricular tachycardia, second- to third-degree atrioventricular block, uncontrolled atrial tachycardia (including atrial flutter, atrial fibrillation, etc), mural thrombus, cardiac aneurysm, dysfunction or rupture of papillary muscle, severe sinus bradycardia (heart rate <50 beats/min), sinus arrest, etc; (3) history of cardiac arrest; (4) acute noncardiogenic complications, such as infections, kidney failure, hyperthyroidism, etc; (5) severe cardiovascular conditions: moderate to severe valvular stenosis, hypertrophic cardiomyopathy, other forms of ventricular outflow tract stenosis, acute myocarditis, pericarditis, active endocarditis, suspected or known aneurysm rupture, acute pulmonary embolism, or pulmonary infarction; and (6) vulnerable populations, including patients with mental disorders, critical illness, age <18 years, pregnancy, students or subordinate of principal investigators, employees of the research institute, etc.